Show
Sort by
-
Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMAxGPRC5DxCD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma
-
Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM) : first results from the phase Ib CAMMA 3 study
-
Talquetamab, a GPRC5DxCD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma : updated safety and efficacy results from the Phase lb monumental-2 study
-
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven plus Aza) versus placebo with azacitidine (Pbo plus Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
-
Combinatorial targeting of metabolic vulnerabilities in t-cell leukemia through NAMPT inhibition
-
Fixed-duration epcoritamab plus R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3-5) led to sustained remissions and disease-free survival beyond 3 years : results from the EPCORE NHL-2 trial
-
Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT) : 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial
-
Epcoritamab with rituximab plus lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL) : 3-year outcomes from epcore NHL-2 arms 6 and 7
-
Sox11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice
-
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL) : phase 2 ELARA 5-year update